Authors
Latest:
Closing Thoughts on the MDS Treatment LandscapeFollowing its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Latest:
Looking Ahead: Unmet Needs in AML ManagementA look at emerging treatments and remaining unmet needs in the overall treatment landscape for acute myeloid leukemia.
Latest:
Robotic Navigational Bronchoscopy Advances Diagnosis of Early-Stage Lung CancerNathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.
Latest:
Building Upon ScaffoldsCancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.
Latest:
Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate CancerEvangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.
Latest:
Dr Hanna on the FDA Approval of Toripalimab in Nasopharyngeal CarcinomaGlenn J. Hanna, MD, discusses the significance of the FDA approval of toripalimab for patients with recurrent or metastatic nasopharyngeal carcinoma.
Latest:
Dr Basu on the Potential Utility of MRD-Guided Adjuvant Therapy in RCCArnab Basu, MD, MPH, FACP, discusses the phase 2 MRD Gate RCC trial of molecular residual disease–guided adjuvant therapy in in renal cell carcinoma.
Latest:
Risk- and Response-Adaptive Strategies Illuminate New Directions for Multiple MyelomaAlthough cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.
Latest:
Dr Dhanji on Hypertension as a Risk Factor for Mortality in Urothelial CancerSohail Dhanji, MD, discusses the investigation of preoperative hypertension as a risk factor in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, as well as other risk factors for mortality in this patient population.
Latest:
Next-Generation Sequencing Minimal Residual Disease Testing in Blood Cancer Is Needed Now More Than EverSponsored Content by Adaptive Biotechnologies
Latest:
Dr. Hahn on the Impact of Trastuzumab Emtansine in HER2+ Breast CancerOlwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.
Latest:
Unmet Needs and the Future of HER2+ Breast Cancer TreatmentThe panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed.
Latest:
Dr. Cho on the Updated Efficacy of Repotrectinib in TKI-Naïve ROS1+ NSCLCByoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.
Latest:
A Primer on Rising Medical Cannabis Use in OncologyUnsurprisingly, the use of cannabis in patients with cancer appears to be increasing as more and more states are adopting cannabis legislation, both for medical and adult use.
Latest:
New Precision Medicine and Developmental Therapeutics Cancer Clinic Opens at Allegheny General HospitalThe Allegheny Health Network Cancer Institute announced today that it has established one of the region’s first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.
Latest:
Dr Johnson on Trastuzumab Plus Paclitaxel in HER2+ Breast CancerKai Conrad Cecil Johnson, MD, discusses key invasive disease-free survival findings from the final 10-year analysis of the phase 2 APT trial and HER2DX exploratory analyses in patients with HER2-positive breast cancer.
Latest:
Dr Chari on Current Unmet Needs to Address in Multiple Myeloma TreatmentAjai Chari, MD, discusses unmet needs in multiple myeloma, as well as what oncologists should know about the current treatment paradigm for this disease.
Latest:
Dr Feun on the Evolving Treatment Paradigm in HCCLynn G. Feun, MD, discusses the evolution of treatment approaches in hepatoceullar carcinoma, the influence of immunotherapies on patient outcomes in this armamentarium, and ongoing avenues of investigation within in the field of HCC management.
Latest:
Dr. Hassan on the Mechanism of Action of Talazoparib in TNBCSaima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.
Latest:
Dr Lowentritt on the Exploration of Active Surveillance in Prostate CancerBenjamin H. Lowentritt, MD, FACS, discusses the exploration of active surveillance in patients with prostate cancer.
Latest:
WCLC Updates in Small Cell Lung CancerPanelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.
Latest:
Dr Pachynski on the Ongoing Investigation of ARX517 in Advanced Solid TumorsRussell Pachynski, MD, discusses the ongoing investigation of ARX517 in patients with advanced solid tumors in the phase 1/2 APEX-01 trial.
Latest:
Dr Morelli on the Ongoing Investigation of A2B530 in Advanced or Metastatic Solid TumorsMaria Pia Morelli, MD, PhD, discusses the ongoing investigation of A2B530, a Tmod™ CAR T-cell therapy, in advanced or metastatic solid tumors and highlights forward-facing research with the agent.
Latest:
Dr. Erogolu on the Rationale for Investigating Patterns in BRAF+ Metastatic MelanomaZeynep Eroglu, MD, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.
Latest:
Unmet Needs in the Treatment of HR+/HER2- Breast CancerClosing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.
Latest:
Dr Mina on the Evolution of T-DM1 and T-DXd in HER2+ Breast CancerLida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.
Latest:
Dr. Sperling on Future Research With CAR T-Cell Therapy in Multiple MyelomaAdam Sperling, MD, PhD, discusses future research with CAR T-cell therapy in multiple myeloma.
Latest:
Cracking the Cancer Code Requires Both Quiet and ChaosMatthew L. Meyerson, MD, PhD, is constantly curious, both about the world and the people around him and as one of the top cancer researchers on the planet, he has a talent for elevating younger scientists, turning obstacles into discoveries, and sensing future research opportunities.
Latest:
Dr. Gorlick on the Challenges of Identifying Immunotherapeutic Targets in OsteosarcomasRichard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.
Latest:
Dr. Indini on the Rationale for the PULSAR Trial in Classic Kaposi SarcomaAlice Indini, MD, discusses the rationale for the phase 2 PULSAR trial in classic Kaposi sarcoma.
